Age-Related Divergence of Risk-Benefit Relationship of Spironolactone Treatment for Heart Failure With Preserved Ejection Fraction

JACC Heart Fail. 2019 Dec;7(12):1029-1031. doi: 10.1016/j.jchf.2019.09.006.

Authors

Dalane W Kitzman¹, Bharathi Upadhya²

Affiliations

¹ Cardiovascular Medicine Section, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina. Electronic address: dkitzman@wakehealth.edu.
² Cardiovascular Medicine Section, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina.

No abstract available

Keywords: HFpEF; aging; spironolactone.

Publication types

Editorial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Heart Failure*
Humans
Mineralocorticoid Receptor Antagonists
Risk Assessment
Spironolactone*
Stroke Volume

Substances

Mineralocorticoid Receptor Antagonists
Spironolactone

Grants and funding